Deep-tech biomedical research startup Inventia Life Science is building a new laboratory, R&D and manufacturing hub in Sydney with support from the NSW government.
The biotech printing facility will create more than 75 new jobs as it expands from 430 square meters to approximately 1,500 square meters in what will also become Inventia’s Australian headquarters in the industrial suburb of Alexandria.
Inventia is a world leader in 3D cell culture and bioprinting and today creates tools for advanced biomedical discovery. They build printers and formulate bio-inks that allow printing human cells into three-dimensional structures to create human tissue for research and therapy purposes for cancer research, pharmaceuticals discovery and medicine.
The development was supported by the The NSW Government Jobs Plus Program.
An artist’s impression of the new Inventia labs in Sydney’s Alexandria
Last year, Inventia raised $35 million in a Series B led by Blackbird Ventures, backed by Skip Capital, Kim Jackson’s family VC and Atlassian’s Scott Farquhar; and healthcare super fund HESTA.
The aid will go to infrastructure to increase Inventia’s current production capacity for its international commercial expansion.
The company is currently transitioning from an initial soft-launch phase of the RASTRUM 3D bioprinter and biomaterials to full commercial scale-up.
Founder and CEO Dr. Julio Ribeiro said the company has seen strong international and domestic demand from top 10 pharmaceutical companies and research institutes for RASTRUM.
“We are delighted with the support we have received from the NSW Government. The Jobs Plus grant has enabled us to scale our production capacity, hire more highly skilled people, including biologists, software and mechanical engineers, and bring this revolutionary technology to the world,” he said.
“Inventia’s drop-on-demand 3D bioprinting technology is the most advanced and accurate 3D printing of its kind in the world. It is well placed to consolidate Australia as a world leader in this field. These additional funds will help us strengthen Australia’s position and expand our global presence.”
Dr. Ribeiro said new company-wide roles in life science, manufacturing and production, go-to-market, finance and operations, software engineering and customer support will be developed when the facility opens next year.
The government funds will also be used to expand support for new hire training programs to upskill their deep technical engineering and product management skills.
READ NOW: Inventia Life Science raises $35 million on Series B
Contents
